依西美坦治疗绝经后妇女晚期乳腺癌的临床疗效观察

目的：研究依西美坦治疗绝经后妇女晚期乳腺癌的近期疗效及不良反应。方法：采用随机双盲对照方法将48例绝经后晚期乳腺癌患者分为治疗组（依西美坦组，23例）和对照组（来曲唑组，25例）治疗8周。治疗前及治疗第4周、第8周分别检测血中雌二醇（E2）水平，同时观察疗效和不良反应。结果：治疗组与对照组治疗有效率分别为39．1％（9／23）与28．0％（7／25）。ER阳性者的疗效较阴性者好；软组织和骨转移者的疗效明显较肝、肺及内脏转移者好；2组治疗后对E2的平均有效抑制率分别为32．5％和55．1％，治疗组的胃部不适，恶心、呕吐、颜面潮红等不良反应发生率显著低于对照组。结论：依西美坦对E2的抑制作用和对绝经后晚期乳腺癌的疗效肯定，不良反应较轻。

Clinical Study of Postmenopausal Women Patients with Late Breast Cancer Treated with Exemestane

Objective This study was designed to investigate the effect and side effect when exemestane was delivered to postmenopausal women patients with late breast cancer.Methods The selective patients were divided into Group A(23 patients) and Group B(25 patients),who took exemestane and letrozol with randomly double blind control test for 8 weeks.E2 levels were examined during pretreat and treat in the forth and the eighth week,meanwhile clinical effect and side effect were observed.Results The effective rate of Group A and Group B was 39.1% and 28.0%,respectiuely.With regard to effect,postive ER was significantly prior to negative ER and soft tissue and bone metastasis was prior to liver,lung and internal organ metastasis as well.Post treatment mean effective restrained rates for E2 level were 32.5% and 55.1%,respectiuely.Group A had less side effect than Group B,such as uncomfortable stomach,nausea,vomit,red face.Conclusion It is certain that exemestane may restrain E2 level and may be effective for postmenopausal women late breast cancer.Side effect is less.